The Defiance Daily Target 2X Long NVO ETF is a leveraged single-stock exchange-traded fund that seeks daily investment results, before fees and expenses, equal to two times (200%) the daily percentage change in the share price of Novo Nordisk (NVO), a Danish pharmaceutical company focused on diabetes, obesity, and other chronic conditions. NVOX does not invest directly in the underlying security. Instead, the actively managed, non-diversified fund pursues its objective through swap agreements and listed options, while holding U.S. Treasury bills and money-market instruments as collateral.
The fund launched in December 2024 and carries a net expense ratio of approximately 1.3%. With roughly $35 million in assets under management (AUM), it is a compact, tactically oriented vehicle. Because the entire portfolio is built around a single company, sector exposure is effectively 100% Novo Nordisk exposure, amplified by leverage. This concentrated structure explains the fund's outsized volatility: every move in the underlying ADR is roughly doubled on a daily basis. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.
Over the past 30 days, NVOX fell about 10%, from a closing price near $10.05 to roughly $9.02. The decline was not linear. The fund rallied sharply in early November, briefly climbing above $11.40, before giving back all of those gains and trading lower into the middle of the month. The result was a volatile, range-bound-to-lower pattern rather than a smooth downtrend.
The longer view is steeper. Over the past quarter, NVOX has declined approximately 39%, from a closing level near $14.83 to the current price. The gap between the 30-day move and the quarterly move illustrates a key feature of leveraged products: daily rebalancing and the mathematical effects of compounding can cause multi-week returns to diverge meaningfully from a simple multiple of the underlying stock's return, particularly during choppy markets. From what I see, this is important because it highlights the risks of holding these instruments beyond short periods.
The dominant driver over the last 30 days was the performance of Novo Nordisk itself. In early November, the company reported third-quarter results that beat expectations and raised its full-year guidance, powered by strong demand for its GLP-1 (glucagon-like peptide-1) medicines, including the oral Wegovy weight-loss pill. The ADR jumped roughly 5%, and NVOX, with its 2x leverage, surged in tandem.
That rally proved short-lived. Subsequent sessions saw the gains reverse as investors refocused on structural concerns: lower U.S. list prices scheduled to take effect, the expiration of semaglutide patent protection in several markets, and persistent competitive pressure from Eli Lilly (LLY) in the obesity segment. Because NVOX magnifies daily moves, a modest pullback in the underlying translated into a proportionally larger decline in the fund.
The quarterly drawdown reflects a broader, multi-month repricing of Novo Nordisk shares rather than any single event. Entering the period near $14.83, NVOX fell steadily through September and October as investors weighed slowing growth, the loss of U.S. market-share leadership to Eli Lilly, and uncertainty around the company's next-generation pipeline, including the CagriSema obesity candidate. Early-stage oral weight-loss competition and the erosion of pricing power added to the cautious tone.
For a leveraged single-stock fund, these headwinds were amplified mechanically. Even when the underlying stabilized on a given day, the cumulative effect of down days and the fund's daily reset weighed on long-term returns. The result is a fund whose quarterly decline substantially exceeded the underlying stock's own move, underscoring why leveraged products are designed primarily for short-term tactical use rather than buy-and-hold positioning. I’m watching this closely as the volatility decay plays out.
The outlook for NVOX is tied almost entirely to Novo Nordisk's fundamentals and the competitive dynamics of the obesity and diabetes market. Key factors to monitor include the regulatory decision and potential U.S. launch of CagriSema, the international rollout of the oral Wegovy pill, and the impact of lower list prices and semaglutide patent expirations on revenue growth. Continued progress by Eli Lilly and other competitors will also shape sentiment.
Investors should additionally weigh the structural risks of leveraged products, including daily rebalancing, volatility decay, and the potential for returns to diverge from a simple 2x multiple of the underlying over holding periods longer than a single day. These characteristics make NVOX best suited for experienced investors with a short-term tactical view, and they remain central to any forward-looking assessment of the fund.
In my own workflow, Tickeron’s AI Screener has become a go-to resource for quickly scanning leveraged ETFs and single-stock products like NVOX. It pulls together technical indicators, fundamentals, volatility data, and performance metrics across thousands of securities, helping surface patterns or shifts that might otherwise take hours to identify manually. For anyone tracking concentrated or thematic vehicles, it offers a practical way to compare options and stay on top of changing market conditions without overcomplicating the process.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Indicator for NVOX moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 10 instances where the indicator moved out of the overbought zone. In 10 of the 10 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVOX as a result. In 29 of 29 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NVOX turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 11 similar instances when the indicator turned negative. In 11 of the 11 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NVOX moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVOX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for NVOX crossed bullishly above the 50-day moving average on November 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 6 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVOX advanced for three days, in 88 of 99 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
NVOX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 54 of 65 cases where NVOX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.